Lexeo Therapeutics (LXEO) said Monday that interim data from two clinical trials showed that its gene therapy candidate LX2006 led to "clinically significant" improvements in cardiac biomarkers and functional measures across all dose cohorts for Friedreich ataxia, or FA, cardiomyopathy.
The company said its phase 1/2 trial and Weill Cornell Medicine's phase 1a study also showed that the experimental treatment was associated with increased frataxin protein expression in all participants with cardiac biopsies.
Chief Development Officer Sandi See Tai said the data show LX2006 exceeds the thresholds aligned with the US Food and Drug Administration to support accelerated approval in a registrational study expected to begin in early 2026.
The company said it expects to begin enrollment in Q2 for the registrational study with a potential efficacy readout in 2027.
Lexeo shares were up more than 14% in Monday's premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。